Olezarsen治疗严重高甘油三酯血症及胰腺炎风险
两项双盲随机安慰剂对照试验(CORE-TIMI 72a和CORE2-TIMI 72b)纳入严重高甘油三酯血症患者,按1:1:1随机接受Olezarsen 50 mg、80 mg或安慰剂每月一次治疗12个月。主要终点为6个月时甘油三酯水平较基线的百分比变化(安慰剂校正)。结果显示,Olezarsen两个剂量组6个月甘油三酯降幅均显著大于安慰剂(所有比较P<0.001),且急性胰腺炎发生率低于安慰剂(平均率比0.15,95%CI 0.05-0.40,P<0.001)。80 mg剂量组肝酶升高和血小板减少更常见,并观察到肝脂肪分数呈剂量依赖性增加。
要点
- 在严重高甘油三酯血症患者中,Olezarsen 50 mg和80 mg每月一次治疗6个月,甘油三酯降幅均显著大于安慰剂(所有比较P<0.001)。
- Olezarsen组急性胰腺炎发生率低于安慰剂组,平均率比0.15(95%CI 0.05-0.40,P<0.001)。
- CORE-TIMI 72a中6个月甘油三酯安慰剂校正最小二乘均值变化:50 mg组-62.9个百分点,80 mg组-72.2个百分点。
- CORE2-TIMI 72b中6个月甘油三酯安慰剂校正最小二乘均值变化:50 mg组-49.2个百分点,80 mg组-54.5个百分点。
- 80 mg剂量组肝酶升高和血小板减少(血小板计数<100,000/μL)更常见,并观察到肝脂肪分数呈剂量依赖性增加。
适用人群与场景
- 严重高甘油三酯血症患者,来自CORE-TIMI 72a和CORE2-TIMI 72b两项试验,共1061例纳入主要分析(CORE-TIMI 72a 617例,CORE2-TIMI 72b 444例)。
处置流程与药物剂量
- Olezarsen 50 mg或80 mg每月一次皮下注射(原文未明确给药途径,仅写monthly for 12 months),疗程12个月;对照为安慰剂。
研究设计与关键结果
- 研究类型:两项双盲、随机、安慰剂对照试验(CORE-TIMI 72a和CORE2-TIMI 72b);样本量:主要分析共1061例(CORE-TIMI 72a 617例,CORE2-TIMI 72b 444例);人群:严重高甘油三酯血症患者;干预与对照:Olezarsen 50 mg、80 mg或安慰剂每月一次治疗12个月,按1:1:1随机分配。
- 主要终点:6个月时甘油三酯水平较基线百分比变化(安慰剂校正)。CORE-TIMI 72a:50 mg组-62.9个百分点,80 mg组-72.2个百分点;CORE2-TIMI 72b:50 mg组-49.2个百分点,80 mg组-54.5个百分点;所有Olezarsen与安慰剂比较P<0.001。
- 关键次要终点:12个月甘油三酯变化及6个月和12个月载脂蛋白C-III、残粒胆固醇、非高密度脂蛋白胆固醇变化,Olezarsen组降幅均大于安慰剂(所有比较P<0.001)。
- 急性胰腺炎发生率:Olezarsen组低于安慰剂组,平均率比0.15(95%CI 0.05-0.40,P<0.001)。
- 不良事件:任何不良事件发生率在各试验组间似乎相似;80 mg剂量组肝酶升高和血小板减少(血小板计数<100,000/μL)更常见,并观察到肝脂肪分数呈剂量依赖性增加。
证据类型、等级与局限
- 证据类型:两项双盲、随机、安慰剂对照试验(CORE-TIMI 72a和CORE2-TIMI 72b)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于严重高甘油三酯血症患者,Olezarsen每月一次治疗可显著降低6个月甘油三酯水平并减少急性胰腺炎发生;80 mg剂量组需注意肝酶升高、血小板减少(血小板计数<100,000/μL)及肝脂肪分数剂量依赖性增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger RNA, have not been established in this population.
METHODS: We conducted two double-blind, randomized, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b). Patients with severe hypertriglyceridemia were assigned in a 1:1:1 ratio to receive olezarsen at a dose of 50 mg, olezarsen at a dose of 80 mg, or placebo monthly for 12 months. The primary outcome was the percent change in the triglyceride level at 6 months, reported as the difference between each olezarsen dose group and the placebo group (placebo-adjusted change). Secondary lipid outcomes included the percent change in the triglyceride level at 12 months and in apolipoprotein C-III, remnant cholesterol, and non-high-density lipoprotein (non-HDL) cholesterol at 6 months and 12 months. Acute pancreatitis events were assessed across both trials.
RESULTS: A total of 1061 patients were included in the primary analysis (617 in the CORE-TIMI 72a trial and 444 in the CORE2-TIMI 72b trial). At 6 months, the placebo-adjusted least-squares mean change from baseline in the triglyceride level was -62.9 percentage points in the olezarsen 50-mg group and -72.2 percentage points in the olezarsen 80-mg group in the CORE-TIMI 72a trial and was -49.2 percentage points in the olezarsen 50-mg group and -54.5 percentage points in the olezarsen 80-mg group in the CORE2-TIMI 72b trial (P<0.001 for all comparisons of olezarsen with placebo). Decreases in the levels of triglycerides, apolipoprotein C-III, remnant cholesterol, and non-HDL cholesterol were greater with olezarsen than with placebo (P<0.001 for all comparisons). The incidence of acute pancreatitis was lower with olezarsen than with placebo (mean rate ratio, 0.15; 95% confidence interval, 0.05 to 0.40; P<0.001). The incidence of any adverse events appeared to be similar across trial groups. Elevations in liver-enzyme levels and thrombocytopenia (platelet count, <100,000 per microliter) were more common with the 80-mg dose of olezarsen, and a dose-dependent increase in the hepatic fat fraction was noted.
CONCLUSIONS: Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. (Funded by Ionis Pharmaceuticals; CORE-TIMI 72a and CORE2-TIMI 72b ClinicalTrials.gov numbers, NCT05079919 and NCT05552326.).
参考来源
- Marston NA, Bergmark BA, Alexander VJ, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2025. PMID: 41211918. doi:10.1056/NEJMoa2512761
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。